Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

Trial Profile

Phase 1, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2018

At a glance

  • Drugs Trastuzumab-deruxtecan (Primary)
  • Indications Adenocarcinoma; Advanced breast cancer; Gastric cancer
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 30 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 27 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 18 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top